Immunomodulatory Nanoparticles Enable Combination Therapies To Enhance Disease Prevention and Flare Control in Rheumatoid Arthritis
Open Access
- 6 August 2025
- journal article
- Published by American Chemical Society (ACS) in ACS Central Science
- Vol. 11 (9) , 1581-1597
Abstract
Disease-modifying antirheumatic drugs (DMARDs) have greatly improved the treatment of rheumatoid arthritis (RA), but strategies to prevent disease onset and recurring flares remain limited. While abatacept (CTLA-4 IgG) can delay RA onset and corticosteroids are used for flare control, the benefit is temporary. We report that combining standard-of-care treatments with a locally administered immunomodulatory agent, termed Agg-CLNP, enhances both disease prevention and flare mitigation. Agg-CLNP consists of polymer nanoparticles conjugated with an immunodominant aggrecan peptide and encapsulate calcitriol. These nanoparticles are optimized for uptake by dendritic cells (DC) in lymph nodes proximal to arthritic joints. In vitro, Agg-CLNP suppressed costimulatory molecules and HLA class II (HLA-2) expression and upregulated CTLA-4 in human monocyte-derived DC from healthy and RA donors. In SKG mice, a T cell-driven RA model, Agg-CLNP combined with CTLA-4 IgG synergistically delayed disease onset and reduced severity. In a dexamethasone (Dex) withdrawal flare model, post-Dex Agg-CLNP treatment reduced flare severity and preserved a regulatory phenotype in DC, while suppressing local pathogenic TH17 cells. Next generation RNA sequencing of lymph node DC revealed Ctla4 upregulation and changes in other immunomodulatory genes linked to flare prevention. These findings highlight Agg-CLNP as a potential therapeutic strategy to address critical unmet needs in RA management.Keywords
Funding Information
- Vetenskapsr?det (2021-00997)
- University of California, San Diego
- Stiftelsen Konung Gustaf V:s 80-?rsfond
- Svenska S?llskapet f?r Medicinsk Forskning (S19-0062)
- IngaBritt och Arne Lundbergs Forskningsstiftelse
- Arthritis National Research Foundation
- National Institutes of Health (F31AR083236, P30AR073761, R01AR065466, R01AR081887)
This publication has 71 references indexed in Scilit:
- CCL17, CCL22 and their receptor CCR4 in hematologic malignanciesDiscover Oncology, 2024
- A tolerogenic dendritic cell–based therapy targeting heat shock protein–specific regulatory T cells in rheumatoid arthritis2023
- Abatacept retention and clinical outcomes in rheumatoid arthritis: real-world data from the German cohort of the ACTION study and a comparison with other participating countriesClinical Rheumatology, 2019
- Comparative Effectiveness of Abatacept Versus Tumor Necrosis Factor Inhibitors in Patients with Rheumatoid Arthritis Who Are Anti-CCP Positive in the United States Corrona RegistryRheumatology and Therapy, 2019
- Diagnosis and Management of Rheumatoid ArthritisJAMA, 2018
- Decreased CD200R expression on monocyte-derived macrophages correlates with Th17/Treg imbalance and disease activity in rheumatoid arthritis patientsInflammation Research, 2014
- Antigen‐specific suppression of established arthritis in mice by dendritic cells deficient in NF‐κBArthritis & Rheumatism, 2007
- Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis: A double‐blind, randomized, placebo‐controlled trialArthritis & Rheumatism, 2007
- HLA markers and prediction of clinical course and outcome in rheumatoid arthritisArthritis & Rheumatism, 1997
- Hla‐dr alleles with naturally occurring amino acid substitutions and risk for development of rheumatoid arthritisArthritis & Rheumatism, 1990